News

Apply now for the ATCC Innovation Challenge

ATCC is excited to launch their 2025 Innovation Challenge, inviting researchers to explore bold, creative applications of their ThawReady™ Assay Ready Cells, an innovative line of products  designed to accelerate cell-based assays and eliminate the need for lengthy cell expansion and banking prior to starting bioassays, saving valuable time and money.

Running through November 30, 2025, the challenge offers researchers an opportunity to win free ThawReady™ products and gain visibility through collaboration with ATCC in webinars, conference showcases, and other scientific platforms. To enter, researchers must submit a short proposal (up to 1000 characters) describing how they plan to use ThawReady™ cells in their innovative research. Winning entries will receive complimentary products and the opportunity to share their work with the broader scientific community.

Two models are available for the challenge:

ThawReady™ THP-1 (TIB-202-AR)

  • Derived from a human monocytic leukemia patient.
  • Ideal for immunology, toxicology, and cancer research.
  • Supports assays such as monocyte differentiation, phagocytosis, and co-culture studies.
  • Preserved in a chemically defined, animal-free formulation.
  • Ready to use upon thawing with ≥80% viability.

 ThawReady™ THP-1 NF-κB-Luc2 (TIB-202-NFkB-LUC2-AR)

  • Engineered to express luciferase under NF-κB control.
  • Enables sensitive, quantitative analysis of NF-κB activation.
  • Demonstrates over 200-fold increase in luminescence upon LPS stimulation.
  • Maintains functionality and morphology post-thaw, even after extended rest periods.
  • Suitable for drug screening, pathway analysis, and biocompatibility testing.

 

Recent News

07/23/2026

Activation Capital Expands the Bio+Tech Center, Doubling Laboratory Capacity to Strengthen Virginia’s Life Sciences Entrepreneurship and Innovation Ecosystem

Activation Capital, the operating name of the Virginia Biotechnology Research Partnership Authority, today announced an expansion of its Bio+Tech Center to support the continued growth of life sciences entrepreneurship across the region. Activation Capital’s Bio+Tech Center is a life sciences incubator located within the Virginia Bio+Technology Research Park. Serving as both a physical and programmatic

07/22/2026

Epidarex Announces Leadership Appointments

With the launch of our latest fund, Epidarex Capital IV, LP, we are pleased to announce several promotions. As we continue to grow and deepen our impact across the US and UK life science ecosystems, recognizing and elevating exceptional talent within our team is a vital part of that journey. These transitions reflect our continued

07/22/2026

Phlow Corp. Appoints Sripathy Venkatraman, Ph.D, As Chief Scientific Officer

Phlow Corp., a U.S.-based advanced pharmaceutical contract development and manufacturing organization (CDMO), dedicated to strengthening the nation’s pharmaceutical supply chain and protecting America’s medicine cabinet, today announced the appointment of Sripathy Venkatraman, Ph.D., MBA, as Chief Scientific Officer. Venkatraman brings more than 25 years of experience in pharmaceutical development, process chemistry, manufacturing, and scientific leadership. He